Dual-modality Micro-positron Emission Tomography/computed Tomography and Near-infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2013 Aug 7

PMID 23918654

Citations 16

Authors

Miao Huang

Chiyi Xiong

Wei Lu

Rui Zhang

Min Zhou

Qian Huang

Jeffrey Weinberg

Chun Li

Affiliations

Soon will be listed here.

Abstract

Purpose: In glioblastoma, EphB4 receptors, a member of the largest family of receptor tyrosine kinases, are overexpressed in both tumor cells and angiogenic blood vessels. The purpose of this study was to examine whether the EphB4-binding peptide TNYL-RAW labeled with both (64)Cu and near-infrared fluorescence dye Cy5.5 could be used as a molecular imaging agent for dual-modality positron emission tomography/computed tomography [PET/CT] and optical imaging of human glioblastoma in orthotopic brain tumor models.

Materials And Methods: TNYL-RAW was conjugated to Cy5.5 and the radiometal chelator 1,4,7,10-tetraazadodecane-N,N',N″,N‴-tetraacetic acid. The conjugate was then labeled with (64)Cu for in vitro binding and in vivo dual μPET/CT and optical imaging studies in nude mice implanted with EphB4-expressing U251 and EphB4-negative U87 human glioblastoma cells. Tumors and brains were removed at the end of the imaging sessions for immunohistochemical staining and fluorescence microscopic examinations.

Results: μPET/CT and near-infrared optical imaging clearly showed specific uptake of the dual-labeled TNYL-RAW peptide in both U251 and U87 tumors in the brains of the nude mice after intravenous injection of the peptide. In U251 tumors, the Cy5.5-labeled peptide colocalized with both tumor blood vessels and tumor cells; in U87 tumors, the tracer colocalized only with tumor blood vessels, not with tumor cells.

Conclusions: Dual-labeled EphB4-specific peptide could be used as a noninvasive molecular imaging agent for PET/CT and optical imaging of glioblastoma owing to its ability to bind to both EphB4-expressing angiogenic blood vessels and EphB4-expressing tumor cells.

Citing Articles

Design Principles and Applications of Fluorescent Kinase Inhibitors for Simultaneous Cancer Bioimaging and Therapy.

Ganai A, Vrettos E, Kyrkou S, Zoi V, Khan Pathan T, Karpoormath R Cancers (Basel). 2024; 16(21).

PMID: 39518106 PMC: 11545566. DOI: 10.3390/cancers16213667.

Eph receptors and ephrins in cancer progression.

Pasquale E Nat Rev Cancer. 2023; 24(1):5-27.

PMID: 37996538 PMC: 11015936. DOI: 10.1038/s41568-023-00634-x.

Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.

Chan M, Huang W, Satpathy A, Su T, Hsiao M, Liu R Pharmaceutics. 2022; 14(2).

PMID: 35214188 PMC: 8875488. DOI: 10.3390/pharmaceutics14020456.

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.

Bolcaen J, Kleynhans J, Nair S, Verhoeven J, Goethals I, Sathekge M Theranostics. 2021; 11(16):7911-7947.

PMID: 34335972 PMC: 8315062. DOI: 10.7150/thno.56639.

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.

Bolcaen J, Nair S, Driver C, Boshomane T, Ebenhan T, Vandevoorde C Pharmaceuticals (Basel). 2021; 14(7).

PMID: 34209513 PMC: 8308832. DOI: 10.3390/ph14070626.

References

Gibson A, Hebden J, Arridge S . Recent advances in diffuse optical imaging. Phys Med Biol. 2005; 50(4):R1-43. DOI: 10.1088/0031-9155/50/4/r01. View

Cheng N, Brantley D, Chen J . The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2001; 13(1):75-85. DOI: 10.1016/s1359-6101(01)00031-4. View

Flanagan J, Vanderhaeghen P . The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 1998; 21:309-45. DOI: 10.1146/annurev.neuro.21.1.309. View

Pasquale E, Deerinck T, Singer S, Ellisman M . Cek5, a membrane receptor-type tyrosine kinase, is in neurons of the embryonic and postnatal avian brain. J Neurosci. 1992; 12(10):3956-67. PMC: 6575947. View

Wang W, Ke S, Kwon S, Yallampalli S, Cameron A, Adams K . A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem. 2007; 18(2):397-402. DOI: 10.1021/bc0602679. View

Zhang R, Xiong C, Huang M, Zhou M, Huang Q, Wen X . Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials. 2011; 32(25):5872-9. PMC: 3110559. DOI: 10.1016/j.biomaterials.2011.04.070. View

Grinvald A, Frostig R, Lieke E, Hildesheim R . Optical imaging of neuronal activity. Physiol Rev. 1988; 68(4):1285-366. DOI: 10.1152/physrev.1988.68.4.1285. View

Durbin L, Brennan C, Shiomi K, Cooke J, Barrios A, Shanmugalingam S . Eph signaling is required for segmentation and differentiation of the somites. Genes Dev. 1998; 12(19):3096-109. PMC: 317186. DOI: 10.1101/gad.12.19.3096. View

Easty D, Herlyn M, Bennett D . Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer. 1995; 60(1):129-36. DOI: 10.1002/ijc.2910600119. View

10.

Furnari F, Fenton T, Bachoo R, Mukasa A, Stommel J, Stegh A . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. DOI: 10.1101/gad.1596707. View

11.

Boyd A, Lackmann M . Signals from Eph and ephrin proteins: a developmental tool kit. Sci STKE. 2001; 2001(112):re20. DOI: 10.1126/stke.2001.112.re20. View

12.

Bremer C, Ntziachristos V, Weissleder R . Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003; 13(2):231-43. DOI: 10.1007/s00330-002-1610-0. View

13.

Nakamoto M, Bergemann A . Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 2002; 59(1):58-67. DOI: 10.1002/jemt.10177. View

14.

Pasquale E . Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005; 6(6):462-75. DOI: 10.1038/nrm1662. View

15.

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

16.

Wicks I, Wilkinson D, Salvaris E, Boyd A . Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci U S A. 1992; 89(5):1611-5. PMC: 48502. DOI: 10.1073/pnas.89.5.1611. View

17.

Xia G, Kumar S, Stein J, Singh J, Krasnoperov V, Zhu S . EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2005; 25(5):769-80. DOI: 10.1038/sj.onc.1209108. View

18.

Niell C, Smith S . Live optical imaging of nervous system development. Annu Rev Physiol. 2004; 66:771-98. DOI: 10.1146/annurev.physiol.66.082602.095217. View

19.

Murai K, Pasquale E . 'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci. 2003; 116(Pt 14):2823-32. DOI: 10.1242/jcs.00625. View

20.

Kumar S, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley E . Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006; 169(1):279-93. PMC: 1698769. DOI: 10.2353/ajpath.2006.050889. View